A61P 3/06
Antihyperlipidemics
A61P3/06 (Antihyperlipidemics) appears on 10,795 US grants and 15,904 published applications in this corpus.
Search patents in A61P- Granted patents
- 10,795
- Published applications
- 15,904
- Assignees
- 4,171
- Inventors
- 25,970
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 14 | 0 |
| 1978 | 17 | 0 |
| 1979 | 20 | 0 |
| 1980 | 21 | 0 |
| 1981 | 28 | 0 |
| 1982 | 29 | 0 |
| 1983 | 18 | 0 |
| 1984 | 36 | 0 |
| 1985 | 22 | 0 |
| 1986 | 30 | 0 |
| 1987 | 38 | 0 |
| 1988 | 41 | 0 |
| 1989 | 57 | 0 |
| 1990 | 61 | 0 |
| 1991 | 65 | 0 |
| 1992 | 86 | 0 |
| 1993 | 50 | 0 |
| 1994 | 61 | 0 |
| 1995 | 94 | 0 |
| 1996 | 84 | 0 |
| 1997 | 112 | 0 |
| 1998 | 133 | 0 |
| 1999 | 137 | 0 |
| 2000 | 147 | 0 |
| 2001 | 163 | 58 |
| 2002 | 192 | 274 |
| 2003 | 221 | 459 |
| 2004 | 196 | 665 |
| 2005 | 162 | 701 |
| 2006 | 242 | 728 |
| 2007 | 304 | 817 |
| 2008 | 322 | 904 |
| 2009 | 361 | 1033 |
| 2010 | 573 | 1209 |
| 2011 | 552 | 1005 |
| 2012 | 632 | 975 |
| 2013 | 747 | 824 |
| 2014 | 706 | 804 |
| 2015 | 665 | 711 |
| 2016 | 488 | 706 |
| 2017 | 478 | 621 |
| 2018 | 419 | 523 |
| 2019 | 407 | 534 |
| 2020 | 350 | 497 |
| 2021 | 337 | 419 |
| 2022 | 240 | 380 |
| 2023 | 189 | 298 |
| 2024 | 175 | 294 |
| 2025 | 175 | 275 |
| 2026 | 87 | 190 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for the treatment of cholesterol crystal embolization with cyclodextrins6 Oct 2026US 12,751,966 B2Beren Therapeutics P.B.C.
- Benzenesulfonamide derivatives and method for modulating lipid raft22 Sep 2026US 12,740,952 B2Gongwin Biopharm Co., Ltd
- Composition for preventing, ameliorating, or treating metabolic syndromes including obesity, diabetes, hyperlipidemia, and fatty liver22 Sep 2026US 12,741,007 B2Nutracore Co., Ltd.
- Preparation comprising anti-PCSK9 antibody and use thereof22 Sep 2026US 12,741,023 B2Innovent Biologics (Suzhou) Co., Ltd.
- Method for treating diabetes by using Antrodia camphorata compound15 Sep 2026US 12,734,148 B2Lantyng Biotechnology Corp.
- Glp-1r/gipr/gcgr triple agonist analogue and use thereof1 Oct 2026US 2026/0295055 A1Shenzhen Bay Laboratory
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Compositions and methods for epigenetic regulation of pcsk9 expression24 Sep 2026US 2026/0284228 A1nChroma Bio, Inc.
- Trpv1 agonist and uses thereof17 Sep 2026US 2026/0274802 A1SciTherm Therapeutics Corporation
- Use of composition containing candesartan or azilsartan10 Sep 2026US 2026/0263425 A1Gachon University of Industry-Academic Cooperation Foundation
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates509US 5,455,233 ABoron Biologicals, Inc. · 1995